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Chapter 11
Measuring the Action of Oligonucleotide Therapeutics
in the Lung at the Cell Type-Specific Level by Tissue
Disruption and Cell Sorting (TDCS)
Helen Graves, Steven Evans, Michael Fauler, Manfred Frick,
and Sterghios A. Moschos
Abstract
The clinical potential of DNA and RNA-targeting therapeutics for airways disease has been hampered by
the poor translation of promising drug candidates from cell culture to in vivo models and the clinic. For
example, classical preclinical approaches routinely report 20–60% target knockdown effects in the lung,
where 1 or 2 log effects are observed in isolated cell cultures in vitro. Preparation of monocellular
suspensions of tissues by mechanoenzymatic disruption followed by cell sorting (TDCS) after in vivo
drug dosing, however, can offer pharmacokinetic and pharmacodynamic insights on the effects of drugs
to precise cell subpopulations. Moreover, this can be reliably achieved with up to 66% fewer animals than
standard in vivo pharmacology approaches due to lower data variance afforded through analytics on
defined, viable cell numbers. Here we describe the TDCS methodology for the isolation of total lung
epithelia, lung macrophages, and epithelium/macrophage-depleted cell fractions frommouse lungs using a
two-stage sorting process of immunomagnetic bead separation followed by flow cytometric sorting using
fluorescent antibodies against well-established surface markers such as F4/80, CD11b, and CD326.
Validated antibodies for additional cell types and markers are also provided.
Key words Lung, Cell type-specific in vivo pharmacology, Oligonucleotides, Fluorescence activated
cell sorting, Magnetic cell sorting, RNAi, siRNA, Antisense, MicroRNA
1 Introduction
Pharmacokinetic and pharmacodynamic assessment of oligonucle-
otide and other DNA or RNA-targeting therapeutics in vivo typi-
cally involves bioanalytical procedures carried out at tissue level.
After following standardized procedures on animal models of dis-
ease, animals are terminally anaesthetized at set time points, tissues
are excised, and homogenized, to extract and purify protein, DNA
or RNA [1]. Analytes are then processed for the measurement of
specific gene/protein expression or, more recently, full proteomic
and transcriptomic analysis. Where possible, drug loading can also
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be assessed (e.g., using mass spectrometry [2], hybridization-based
nucleic acid capture assays, or amplification methods such as PCR),
provided oligonucleotide drug chemistry is compatible with DNA
polymerases. Unfortunately, the 1–2 log knockdown effects of
antisense and short interfering RNA (siRNA) therapeutics typically
measured in cell culture only translates to 40–60% target RNA
reduction at the whole lung tissue level in animals; clinical data
can be even more disappointing [3].
The reasons for these discrepancies have been the subject of
intense debate, speculation, and assumptions, as extensively dis-
cussed elsewhere [3, 4]. From a mathematical perspective, analys-
ing target RNA levels in homogenized lung tissues can only yield
lower levels of drug effect as compared to cell line experiments, due
to poor signal-to-noise ratios. The problem occurs because the
levels of an RNA target measured in an extract from a whole lung
lobe reflect the average level of that RNA molecular species across
the pool of different cell types that constitute the lung tissue.
Furthermore, the relative numbers of each cell type are not fixed
and can vary on account of disease, especially when inflammation is
involved. At the same time, the extent to which target RNA levels
may change on account of oligonucleotide treatment in a given cell
is, as a minimum, a function of oligonucleotide transfection effi-
ciency: this efficiency also varies between cell types. Furthermore, it
is still unknown if downregulation of a target gene in some cells
leads to compensatory gene expression changes in untransfected
bystander cells.
In an ideal scenario, therefore, the effect of an oligonucleotide
drug on a tissue as complex as the lung should be measured by cell
type, and in relation to its degree of transfection. This can be
achieved by applying mechanoenzymatic Tissue Disruption and
Cell Sorting (TDCS) on in vivo pharmacology experiments.
Indeed, industry evidence on what makes for successful drug dis-
covery [5] points to TDCS as a tool that would offer added value to
project decision making. By sorting tissue cells by type, measuring
drug loading, and on-target effect, one can obtain evidence of
target engagement, and an on-target mechanism of action [6] in
cells relevant to disease, in vivo, and potentially even in patients.
Obtaining such pharmacological evidence is now considered piv-
otal to drug development efforts [7].
Many of the tools and materials necessary to implement TDCS
are well-established from basic research studies involving primary
tissue cell isolation. Over the past decade, increasingly complicated
cell separation approaches have been used to study cell type specific
biology in primary human tissue, tumor biopsies, as well as animal
models of disease. Two important methods are fluorescence-
activated cell sorting (FACS), and magnetic cell sorting (MACS).
The FACS method is good for high cell purity and high cell
recovery, low cell surface marker expression, detection of
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intracellular markers, as well as sorting cells by cell surface marker
expression levels. In contrast, MACS, being suitable only for sur-
face markers, is good for bulk cell depletion/enrichment for a
single surface marker (e.g., in the preparation for FACS) or situa-
tions where the optical properties of the cell interfere with marker
sensitivity such as autofluorescence, either in large-scale instru-
ments or microfluidic systems. Recent advances in these platforms
are reviewed by Shields et al. [8]. Studies involving MACS and/or
FACS use either in-house, or supplier prevalidated reagents (anti-
bodies or aptamers) specific to cell surface markers found in cell
subpopulations, or markers accessible after cell fixation and per-
meabilization. Reagent validation usually takes the form of gene
expression/surface marker analysis of sorted cells, cell function
analyses, marker coexpression as observed histopathologically, by
Western blotting, or by alternative means including physicochemi-
cal properties exhibited during flow cytometry [2]. The vast body
of work involving cell sorting can be a very useful resource in
implementing TDCS in in vivo pharmacology studies not only for
lung disease but virtually for any indication with a substantial body
of basic research involving cell sorting methods and appropriate
validation of marker-specific reagents.
Using TDCS we were therefore able to show that oligonucleo-
tide drugs dosed directly into mouse tracheas loaded at appreciable
amounts only in airway/alveolar macrophages but with no statisti-
cally significant effect on a target gene, despite statistical power for
measuring a 50% change exceeding 94% [2]. Histological and
ADME follow-up experiments explained this outcome through
the observation of rapid oligonucleotide transcytosis from the air-
way lumen into circulation, and elimination in urine in as little as
15 min after dosing. Tissues were obtained from animals in accor-
dance with regulations and established guidelines and were
reviewed and approved by an Institutional Animal Care and Use
Committee or through an Ethical Review Board. Although our
results were with modified short interfering RNA (siRNA) and
third generation, short locked nucleic acid (LNA) drugs, the find-
ings were in line with historical pharmacokinetic studies by Ionis
pharmaceuticals on longer, second generation antisense oligonu-
cleotides [9]. This suggested that more recent clinical measure-
ments were not sensitive enough to measure circulatory and urine
oligonucleotide levels in man [3]. Clinical efforts with naked
siRNA and antisense oligonucleotides performed by a number of
pharmaceutical companies were abandoned shortly afterward.
Presently, research on oligonucleotide drugs for respiratory
diseases involves agents that work as toll like receptor agonists,
splice modulating antisense, in vitro transcribed RNA therapeutics
including long noncoding RNAs, mediators of DNA and RNA
editing, and RNA interference modulators (microRNA mimics,
siRNA, and microRNA inhibitors). This is on account of the recent
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regulatory approvals of the antisense drugs mipomersen (familial
hypercholesterolemia), inotersen (hereditary transthyretin-
mediated amyloidosis), nusinersen (spinal muscular atrophy;
drugs developed by Ionis Pharmaceuticals), and eteplirsen (Duch-
enne’s muscular dystrophy; developed by Sarepta Therapeutics),
the siRNA drug patisiran (hereditary transthyretin-mediated amy-
loidosis; developed by Alnylam Pharmaceuticals), as well as unprec-
edented advances involving the development and use of an
antisense drug for a single patient harboring a unique mutation,
also known as “n of 1 medicine,” as exemplified by milasen
[10]. Crucially, all of these drugs effectively load onto disease-
relevant target tissues and cells, either through first pass metabo-
lism (targeting the liver) or by direct intrathecal injection to reach
the central nervous system. Therefore, to achieve comparable suc-
cess in the lung, with few exceptions, investigators are evaluating a
cadre of nanoformulation approaches as drug delivery solutions to
successfully transfect airways cells. Although the safety of particu-
late drug delivery to the lungs is still a substantial outstanding
concern [3, 11, 12], the need remains for determining drug load-
ing and effect in the lung cell types relevant to disease.
In this protocol we therefore detail the approach for processing
an excised mouse lung to sort precise numbers of specific cell types
for appropriate downstream analytics. We describe the steps needed
to successfully prepare monocellular suspensions, and detail the
approach for sorting three cell preparations, each consisting of
20,000 lung epithelial cells, macrophages, or nonepithelial/non-
macrophage cells from a single lung lobe (Fig. 1). The two-stage
sorting protocol first makes use of magnetic bead-based separation,
followed by flow cytometric sorting using fluorochrome conju-
gated antibodies against cell surface markers of interest. This pro-
tocol is therefore an extension to a previously published method for
in vivo RNA therapeutics pharmacology [1], and focuses exclu-
sively on how to implement TDCS. In our hands, TDCS can be
reliably followed up with transcriptomics, proteomics, and mass
spectrometry, as well as subculturing (where cell division is natu-
rally accommodated by the cell type of interest). With the emer-
gence of single cell ‘omics, the anticipated parallelization, and cost
reduction of these newer bioanalytical approaches, we look forward
to TDCS-based in vivo pharmacology delivering highly potent,





a Mouse Lung Lobe
1. Digestion buffer: 2.5% v/v fetal bovine serum (FBS), 0.5 mM
calcium chloride, 0.75 mMmagnesium chloride and 1.5% w/v
DNase I from bovine pancreas (lyophilized powder at >85%
purity, >400 Kunitz units/mg protein; Sigma Aldrich, Dorset,
UK; see Note 1) prepared in Dulbecco’s Phosphate Buffered
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Saline without calcium and magnesium (DPBS). Make fresh
when needed.
2. Collagenase Buffer: 150 units/ml Collagenase 3 (Worthington
Biochemical Corporation, Lakewood, NJ, USA) in digestion
buffer; prepare the night before and keep at 4 C or on ice until
used (see Note 1).
3. Cell resuspension buffer: sterile 1 DPBS supplemented with
5% v/v FBS.
4. Oscillating platform incubator, set at 37 C.
5. gentleMACS tissue dissociator (Miltenyi Biotec Ltd., Woking,
UK).
6. gentleMACS C Tubes (purple), for tissue dissociation (Milte-
nyi Biotec Ltd.; see Note 2).
7. Sterile tissue vials such as 5 ml universals, 15 or 50 ml cell
culture centrifugation tubes.
8. 50 ml sterile, cell culture centrifugation tubes.
9. Sterile 5 ml syringes.
10. Sterile 1 PBS.
11. 18 MΩ deionized water.
12. 3.6% w/v sodium chloride in sterile, deionized water.
13. Cell counting apparatus (hemocytometer and trypan blue or
automated cell counter).
Fig. 1 Cell sorting strategy for the parallel isolation of lung epithelia, lung macrophages and remaining cells
from a single mouse lung lobe digest. In addition to the previously published approach of obtaining
macrophages (CD11b+; F4/80+), epithelia (CD11b; CD45; CD326+) and nonmacrophage/epithelial cells
(CD11b; CD45; CD326), the protocol is amenable to neutrophil isolation (CD11b+, F4/80). For
macrophage-focused work, a simple CD45+, side scatter (SSC) high, fluorescein isothiocyanate (FITC)
autofluorescence high positive selection approach can be reliably implemented
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14. Desktop refrigerated centrifuge with bucket swing out rotor,
for cell culture purposes.
15. 40 μm and 100 μm Cell Strainers.
16. Wet ice.
17. Serological pipettes (25 ml).
18. Serological pipette gun with variable speed control.
19. Sterile spatula(s) (see Note 3).
2.2 Isolation
of Specific Cell Types
from Digested Lung
Tissue
1. autoMACS running buffer: 1 phosphate buffered saline sup-
plemented with 2mMEDTA, 0.5% w/v bovine serum albumin
(BSA), and 0.09% w/v sodium azide, pH 7.2; stored at 4 C for
long-term use.
2. CD11b+ paramagnetic microbeads (Miltenyi Biotech).
3. Compensation beads: anti-rat IgG for the rat anti-mouse anti-
bodies used in this protocol or alternative species as required.
4. BD Biosciences Accudrop beads: Drop delay set up beads
(BD Biosciences, Crawley, UK).
5. Cytometer Setup and Tracking beads (CS and T beads)
(BD Biosciences).
6. Stain buffer: 5% w/v BSA or similar in 1 PBS.
7. 2% BSA supplemented PBS: 2% w/v BSA or similar in 1 PBS.
8. Peridinin Chlorophyll Protein Complex (PerCP) anti-mouse
F4/80 (Thermo Fisher Scientific).
9. Phycoerythrin (PE) anti-mouse CD326 (Biolegend, San
Diego, CA).
10. Fluorescein isothiocyanate (FITC) anti-mouse CD45
(BD Biosciences).
11. 30 μm filter or cell strainer.
12. autoMACS Pro Separator (Miltenyi Biotec Ltd.; see Note 4).
13. Chilled collection blocks for autoMACS Pro (ensure chilled to
4 C prior to use).
14. FACS tubes with 35 μm cell strainer cap.
15. Cell sorter capable of analysing four fluorochromes and
depositing sorted cells into a 96-well plate (e.g., BD FACS
Aria (BD Biosciences); see Note 5).
16. Uncoated, sterile, cell culture 96-well plates (round or flat
bottom) appropriate to the downstream analytical approach
to be used.





a Mouse Lung Lobe
1. Rinse the fresh, perfused mouse lung, with sterile PBS to
eliminate any blood.
2. Transfer the lung lobe to 2 ml of digestion buffer in a sterile
tissue vial (ensure full tissue submersion) and keep on ice until
all lungs are harvested.
3. Transfer tissue into a gentleMACS C tube using a sterile
spatula and add 5 ml of Collagenase Buffer per tube (see
Notes 6 and 7).
4. Close the gentleMACS C tube using the provided impeller cap
(see Note 8).
5. Mix by gentle inversion three times.
6. Keep on ice until all lungs are prepared.
7. Once all the lungs for your experiment are prepared, process
them sequentially on the gentleMACS tissue dissociator by
placing the tubes, inverted, onto the device, and running pro-
gram m_lung_01.01 provided by the supplier, to disrupt the
tissue.
8. Transfer the gentleMACS C tubes onto an oscillating platform
incubator set at 37 C and shake at 250 rpm for 30 min.
9. Return the gentleMACS C tubes onto the gentleMACS tissue
dissociator and process the samples using program
m_lung_02.01 to achieve monocellular suspensions.
10. Pulse-centrifuge the gentleMACS C tubes for 10 s at 400  g
to collect cells at the bottom of the tube.
11. Assemble a 50 ml centrifugation tube per lung lobe with a
40 μm cell strainer.
12. Pass the cells through the 40 μm cell strainer using a 5 ml
syringe plunger.
13. Rinse the strainer with 3  1 ml of digestion buffer into the
50 ml centrifugation tube.
14. With the strainer still attached to the centrifuge tubes, centri-
fuge the cells at 400  g, 4 C for 10 min, to improve cell
recovery rate.
15. Carefully remove and discard the supernatant without disturb-
ing the cell pellet.
16. Resuspend the cells in 4 ml of cell resuspension buffer by gentle
mixing using a 25 ml serological pipette, and keep on wet ice or
at 4 C.
17. Add 20 ml of deionized water; quickly cap the tube and invert
to mix.
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18. After 20 s make the solution isotonic by adding 8 ml of 3.6%
w/v sodium chloride (see Note 9).
19. Centrifuge the cells at 400  g, 4 C for 10 min.
20. Carefully remove and discard the supernatant without disturb-
ing the cell pellet.
21. Resuspend the cells in 5 ml cell resuspension buffer.
22. Count your cells, for example, by trypan blue exclusion assay
on a hemocytometer (mix 25 μl of Trypan Blue with 25 μl of
cell suspension and load onto the hemocytometer; count as per
hemocytometer manufacturer instructions) or automated cell
counting apparatus.
23. Storeon iceorat4 Cuntil cell sorting is carriedout (seeNote10).
3.2 Isolation
of Specific Cell Types
from Digested Lung
Tissue
Due to the high intrinsic autofluorescence of tissue resident macro-
phages which can make flow cytometric analysis more challenging
and limit the choice of fluorochromes, a two-stage separation pro-
tocol is advised whereby macrophages and other myeloid cells are
first removed in bulk using CD11b-specific paramagnetic beads,
followed by flow cytometric staining and cell sorting (see Note 11;
Fig. 1).
There are a large range of kits and reagents commercially
available for the immune-magnetic isolation or depletion of partic-
ular cell types in a blood or tissue sample. Magnetic microbeads are
coupled to antibodies specific for cell surface epitopes and when
combined with a magnetic field, the desired cell type can be isolated
or undesired cell types removed. This section describes the use of
Miltenyi MACS reagents and equipment but the methods
described could be carried out with equivalent reagents from
other sources. Similarly, the fluorochromes used can be adapted
to the capability of the cell sorter and fluorescent antibodies are
available from a wide range of commercial suppliers. Table 1 sum-
marizes antibody suppliers which have proven reliable in our hands
when applying TDCS in pharmacological studies (all reagents were
used at the manufacturer’s recommended concentration).
3.2.1 Separation
of CD11b+ Cells Using
autoMACS Pro
1. Retain at least 0.5 ml of each digested lung sample and store at
4 C. Run the remaining sample through the autoMACS Pro as
described below.
2. Spin digested lung sample(s) at 400  g for 5 min to pellet the
cells and resuspend them in autoMACS running buffer at 10E7
cells per 80 μl.
3. Pass the sample through a filter to ensure a single cell
suspension.
4. Add 20 μl of CD11b-specific microbeads per 10E7 cells and
incubate at 4 C for 15 min (see Note 12).
194 Helen Graves et al.
5. If not done previously during the incubation, turn on and
prime the autoMACS machine and ensure prechilled collection
blocks are removed from the fridge.
6. Wash the samples with 1 ml ice-cold autoMACS running buffer
and spin at 400  g.
Table 1
Antibodies validated for compatibility with TDCS on live or fixed cells
Species Target and clone Supplier and cat. no. Application
Mouse CD105; 209701 BD Biosciences, R and
D Systems
FAB1320A
Endothelial cells or activated macrophages,
positive selection; can discriminate the two
populations by granularity
Mouse CD45; 30-F11 BD Biosciences
557659, 557235
Type I epithelial cell negative selection;
Leukocyte positive selection; Macrophage
cell positive selection
Mouse F4/80; BM8 Invitrogen MF48021 Positive selection of macrophages in a
CD11b population; F4/80 negative
selects for neutrophils
Mouse CD144; 55-7H1 BD Biosciences
560411
Endothelial cell positive selection
Mouse CD326; G8.8 Cambridge
Biosciences 118205,
Biolegend 118205
Epithelial cell positive selection in a CD45,
CD11b population
Mouse CD11b; M1/70 Miltenyi Biotech
130-049-601
Paramagnetic bead positive selection of
macrophages, neutrophils, NK cells,
granulocytes and dendritic cells (requires
F4/80+ downstream for macrophage
selection) and negative selection for





Abcam ab24751 Alveolar type II epithelial cells, positive
selectiona
Rat EpCAM; polyclonal Abcam ab71916 Epithelial cells, positive selectiona
Rat CD45; OX1 eBioscience 12-0461 Negative selection for epithelial enrichmentb
Rat CD68; ED1 Abcam ab31630 Macrophages, positive selectionb
Rat CD45; REA450 Miltenyi Biotec
130-109-682
Paramagnetic bead negative selection for




CD90.1; His51 Miltenyi Biotec
130-094-523
Paramagnetic bead positive selection for T
cellsb
Human TLR2; TL2.1 Invitrogen 16203 Positive selection for epithelial cellsb
Include SSC and FITC channel autofluorescence in selection criteria
aUseful for paraformaldehyde-fixed and saponin-permeabilized cells only
bValidated on live cells only
In Vivo Cell Type-Specific Oligonucleotide PK/PD 195
7. Discard the supernatant and resuspend in 500 μl autoMACS
running buffer.
8. Run samples on the autoMACS, using the “deplete_s” pro-
gram followed by a quick wash between each sample.
9. Both the CD11b+ and CD11b fraction are collected into the
prechilled collection block.
10. Spin samples down at 400  g and resuspend in 100 μl stain
buffer (seeNote 13; see Fig. 2 for a typical forward scatter/side
scatter (FSC/SSC) plot of the CD11b+ and CD11b
fractions).
Fig. 2 (a) Representative scatter plots of digested lung samples prior to CD11b depletion and the CD11b
(left) or CD11b+ (right) fractions following separation. (b–d) Histograms comparing the CD11b population to
the CD11b+ population in terms of CD11b (b), CD326 (c), and CD45 (d) expression.





Keep aside sufficient cells to set up appropriate controls as exem-
plified in Fig. 3 (see Notes 14–16).
1. Stain the fractions of CD11b cells with anti-CD45 and anti-
CD326 to identify leukocytes and epithelial cells (see Fig. 1).
2. Stain the fractions of CD11b+ cells with F4/80 to discriminate
macrophages.
3. Use 20 μl of each antibody in a total volume of 100 μl cell
resuspension buffer.
4. Incubate at 4 C for 30 min.
5. At the same time, create single color controls for compensation
by adding 1 drop of compensation beads to 100 μl cell resus-
pension buffer and incubate with 20 μl of one antibody for
30 min at 4 C.
6. Wash samples and compensation beads with 1 ml stain buffer
and spin at 400  g for 5 min.
Fig. 3 Example of gating controls in flow cytometric analysis. CD11b fractions were stained with two
antibodies, making them appropriate for Fluorescence Minus One (FMO) controls. An example PE FMO (FITC
antibody only) is shown in (a), and an example FITC FMO (PE antibody only) is shown in (b). The CD11b+
fraction was only stained with one antibody so here an FMO was not appropriate; instead, an APC conjugated
isotype control was used as negative control to gate for F4/80 positive cells, with an example shown in (c)
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7. Resuspend the beads in 2 ml stain buffer and filter into a FACS
tube to ensure a single cell suspension ready for analysis and
sorting on the BD FACS Aria.
8. To allow accurate gating of populations, create an FMO (Fluo-
rescence Minus One) control for each antibody used. For
example, the PE FMO control will contain every antibody
used except the PE antibody.




Cells into 96-Well Plates
for Downstream Assays
1. Set up the BD FACS Aria with a 70 μm nozzle and the pressure
setting of medium drop drive frequency 60,000 with a “Purity”
sort setting (e.g., 16-32-0; see Note 17).
2. Run BD CS&T beads to confirm Aria laser performance.
3. Run BD Accudrop beads to set up the drop delay and to align
the 96-well plate.
4. Ensure SSC-W, SSC-H, FSC-W and FSC-H are enabled to
allow doublet discrimination.
5. Add 100 μl of 5% BSA-supplemented PBS to each well of a
96-well plate.
6. Perform compensation using the single stained controls.
7. Take the third of the original sample that was not passed
through the autoMACS Pro and spin at 400  g to pellet.
8. Resuspend in 2 ml 2% BSA-supplemented PBS—this is the
“mixed” population of cells and does not requiring any specific
sorting but requires the correct number of live cells to be
counted into the 96-well plate.
9. Gate the live, single cells on the basis of FSC/SSC. Sort 30,000
cells from within this gate into the appropriate well of a 96-well
plate.
10. Run the CD11b+ population through the Aria and gate on live
single cells and then on F4/80+ cells to sort 30,000 macro-
phages (Fig. 4a).
Fig. 4 Example of gating strategies for CD11b+, F4/80+ macrophage cells (a), CD11b CD326+ epithelial
cells (b), and CD11b CD326 nonepithelial cells (c)
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11. Run the CD11b population through the Aria and gate on
cells that are live/CD45/CD326+ to sort 30,000 epithelial
cells (Fig. 4b).
12. Continue to run the CD11b population, gating on cells that
are live/CD45/CD326 to sort 60,000 nonepithelial cells
(Fig. 4a) (see Notes 18–20; Figs. 3 and 4).
4 Notes
1. The source of DNase I, but more so collagenase, impacts
significantly on process success and cell viability at completion
of the TDCS process. This particular collagenase is sold as low
protease activity which makes it also more appropriate for cell
sorting applications. Although we have not tested the protease
activity of the particular DNase I enzyme supplied from Sigma,
we have not evaluated other enzymes in our workflow for
impact on cell viability.
2. Important! Do not use the M tubes as these homogenize the
tissue by vigorous mechanical shearing stress.
3. For infectious models/microbiome studies ensure that separate
sterile spatulas are used per tissue.
4. The autoMACS Pro instrument was used to standardize multi-
ple separations and help increase throughput but is not an
absolute requirement. During method development, individ-
ual single use columns were used for some experiments and an
acceptable throughput could be achieved in this manner with
sufficient operators, although care would need to be taken to
standardize technique.
5. The sorter used by the authors was a BD FACS Aria with
488 nm blue laser and 633 nm red laser. The laser and filter
combinations available on any particular cell sorter will dictate
the fluorochromes and combinations that can be used during
cell sorting. If an instrument does not have a plate collection
option, up to four populations can be sorted into tubes for later
transfer to appropriate plates. It is worth bearing in mind
though that at least one factor in the improved coefficients of
variation observed with this method is the accurate deposition
of defined cell numbers by the instrument—the equivalent of
which is unlikely to be achieved manually.
6. For highly fibrous tissue (e.g., fibrosis models) it is advised to
mince the tissue down into 1 mm3 cubes first using a sterile
scalpel and petri dish or an automated tissue chopping station
before loading it into the gentleMACS C tube.
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7. If a gentleMACS cell dissociator is not available, then skip steps
3–11; instead, process the tissue by mincing as described in the
previous note, transfer it into a sterile vial, suspend in 5 ml
digestion buffer/lung and incubate for 30 min on an oscillat-
ing platform incubator at 37 C. Then triturate through a 5 ml
syringe without a needle ~25 times and subsequently press the
suspension through a 100 μm cell strainer using a sterile syringe
plunger into a 50 ml cell centrifugation tube; push tissue
clumps through the mesh if necessary. Proceed with step 11.
This method is harsher and less reliable than the gentleMACS
procedure in our experience.
8. Do not use normal cell centrifugation tube caps, as these will
not allow the mechanic disruption to proceed.
9. Steps 19 and 20 lyse any remaining red blood cells. This
protocol is suited to other red blood cell lysis procedures
(e.g., to obtain peripheral blood nucleated cells).
10. In our experience, cells will lose minimal viability (2–3%) over
the next 48 h if kept at 4 C and can even be safely shipped
between sites within this timeframe if necessary.
11. CD11b is expressed on murine monocytes and macrophages
but also on neutrophils, NK cells, dendritic cells and some
subsets of activated lymphocytes. Using CD11b-specific mag-
netic separation is therefore not a purification, but an enrich-
ment in one fraction and a reduction of autofluorescent cells in
the other fraction. Further staining of the CD11b+ fraction
allows for further discrimination of cell types of interest.
12. As only one sample can be processed by the machine at a time it
is not recommended to stain all samples simultaneously as
there will be a considerable lag time between staining and
separation for the last samples processed. Subsequent samples
can be stained and washed while previous ones are running
through the machine. For this reason, it is useful (though not
mandatory) to have two people carrying out this part of the
protocol.
13. It is recommended to retain some of each fraction post mag-
netic separation to assess for viability and successful enrich-
ment. A 100 μl sample can be stained with 2.5 μl of anti-
CD11b antibody, incubated for 30 min and then washed
with cell resuspension buffer. For viability, add 2 μl Sytox red,
mix gently and proceed to analysis. Dead cells will stain positive
in the APC channel and a % viability can be determined by
gating on the negative cells.
14. Ideally, all steps will be completed in one day but it is possible
to leave cells overnight at 4 C at this stage for staining and
sorting the following day. Viability was not affected and bio-
marker data showed that populations sorted on day 1 or day
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2 were highly comparable, suggesting that sorting of a lung
digest sample up to 24 h after preparation is an acceptable
strategy when processing large numbers of mice. In our
hands, the maximum throughput of lungs in one day was
12 and each sort (per animal) took approximately 30 min to
achieve the required cell numbers.
15. Compensation controls will be required for most multicolor
sorting experiments. With multilaser instruments it may be
possible to select fluorochromes that avoid the need for com-
pensation by being sufficiently spectrally separate or by being
excited by different lasers. For example, on a four laser instru-
ment, choosing one fluorochrome for each laser line may
remove the requirement for compensation. However, this
should always be checked initially with the appropriate single
color controls. Compensation beads are most suitable in this
instance due to the variable autofluorescence of cell popula-
tions in digested tissues. Unstained beads should be used for
the unstained control, not unstained lung digest sample.
16. When first developing a panel, use irrelevant specificity isotype
control antibodies to rule out nonspecific binding. Once con-
fidence has been established in the antibodies to be used,
isotype controls are not necessary for every experiment and
Fluorescence Minus One (FMO) controls should be used to
set population gates. For example, during method develop-
ment, tests on ten different antibodies sold as luciferase-specific
and compatible with sorting from a variety of suppliers failed to
exhibit antigen specificity with this method; in stark contrast,
no such issues were experienced with all other markers.
17. Depending on the cell type of interest and downstream appli-
cation, a 100 μm nozzle might be more appropriate. The lower
pressure and wider sort orifice causes less stress to sorted cells
but in our hands resulted in poorer sort efficiency and fewer
recovered cells. Viability staining of cells straight after sorting
on a 70% nozzle showed the majority of the cells survived the
sort and in our system those cells were assessed straight away,
meaning that long term survival was not a concern. If down-
stream applications are to include culturing or functional stud-
ies, a 100 μm nozzle would be recommended. A purity sort
mode was used in this protocol but each investigator should
determine their own requirements of yield versus purity for
specific applications. Efficiency on purity sort mode in our
hands ranged from 79% to 95%.
18. The potential combination of cell surface markers and gating
strategies for cell types in a digested mouse lung are very large.
Since this method was developed there have been extensive
studies published looking at full phenotypic characterization
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of cell types in digested mouse lung—both hematological and
structural. The populations identified with the antibodies
described here are rather broad and can be added to or altered
to more precisely identify numerous cell types depending on
the investigator’s specific interests. Staining for cell surface
markers can be considerably more challenging in digested tis-
sue than in blood due to the digestion process itself which may
result in loss of cell surface epitopes. As an example, with the
digestion protocol described herein, the authors had no success
with a variety of anti-cytokeratin antibodies which had been
described to bind strongly and specifically to epithelial cells
which we hypothesize may be due to the loss of those markers
during the digestion process itself.
19. “Fc block” (rat anti-mouse CD16/32) was trialed during
development to prevent interaction of leukocyte Fc receptors
with the Fc region of fluorescent antibodies but it made no
difference compared to no Fc block controls so this was not
continued. Other nonspecific binding was avoided by the pres-
ence of protein in the stain and sort buffers.
20. If fluorescence is being used to track delivery of oligonucleo-
tides, the spectral profile of that dye will need to be considered
in the panel design for cell sorting. For example, the use of
Cy5-labeled oligonucleotides precluded the use of APC as a
fluorochrome in this study.
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